Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Document Control in Clinical Phase – V 2.0

Posted on By

BA-BE Studies: SOP for Document Control in Clinical Phase – V 2.0

Standard Operating Procedure for Document Control during Clinical Phase of BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/120/2025
Supersedes SOP/BA-BE/120/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a systematic and compliant procedure for managing controlled documents during the clinical phase of Bioavailability/Bioequivalence (BA/BE) studies, ensuring integrity, traceability, and accessibility throughout the document lifecycle.

2. Scope

This SOP applies to all controlled documents generated or used during the clinical phase of BA/BE studies including but not limited to Case Report Forms (CRFs), informed consent forms (ICFs), monitoring

reports, logs, SOPs, training records, and facility documentation.

3. Responsibilities

  • Document Control Officer (DCO): Manages document issuance, versioning, archiving, and master list maintenance.
  • Clinical Research Coordinator: Requests documents and ensures accurate use of controlled versions.
  • QA Personnel: Audits document control systems, performs reviews, and approves version changes.
  • Study Team Members: Ensure correct documentation, completion, and timely submission.
See also  BA-BE Studies: SOP for Maintaining Investigator Site File (ISF) - V 2.0

4. Accountability

The Clinical Operations Manager is accountable for ensuring proper document control practices are implemented and maintained as per GCP and regulatory guidelines.

5. Procedure

5.1 Document Classification

  1. Classify clinical documents into:
    • Controlled Documents (e.g., ICF, CRF, SOPs, log templates)
    • Uncontrolled/Internal Records (e.g., subject screening forms, drafts)

5.2 Document Numbering and Versioning

  1. Assign each controlled document a unique identifier:
    • Format: DOC/BA-BE/XXX/YYYY
  2. Update version number with every approved change (e.g., V1.0 to V2.0).
  3. Document version history in Annexure-1: Document Version Control Log.

5.3 Creation and Review

  1. Document drafts are prepared by responsible personnel and submitted to DCO.
  2. DCO routes draft to QA and study team for review and approval.
  3. Once approved, document is locked as “Controlled” and released for use.

5.4 Distribution and Use

  1. Only controlled hard copies or electronically signed PDFs shall be used.
  2. Use Annexure-2: Controlled Document Issuance Register to track recipients and issuance date.
  3. Obsolete versions must be withdrawn, marked “Superseded,” and archived.
See also  BA-BE Studies: SOP for Trial Registration with EudraCT - V 2.0

5.5 Archival and Retrieval

  1. All completed logs, forms, and reports must be filed in the Investigator Site File (ISF) and Study Master File (SMF).
  2. Archive hard copies in lockable fire-resistant cabinets with restricted access.
  3. Maintain digital backups in a validated document management system (DMS).
  4. Record retrievals using Annexure-3: Document Access Log.

5.6 Deviations and CAPA

  1. If incorrect document version is used:
    • Record deviation in Annexure-4: Document Control Deviation Form
    • Initiate root cause analysis and implement CAPA

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • DCO: Document Control Officer
  • CRF: Case Report Form
  • ICF: Informed Consent Form
  • DMS: Document Management System
  • ISF: Investigator Site File
  • SMF: Study Master File
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Document Version Control Log – Annexure-1
  2. Controlled Document Issuance Register – Annexure-2
  3. Document Access Log – Annexure-3
  4. Document Control Deviation Form – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • WHO GCP Handbook
  • 21 CFR Part 11 – Electronic Records and Signatures
See also  BA-BE Studies: SOP for Sample Storage at -20°C and -70°C - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Document Version Control Log

Document Title Doc No. Version Effective Date Status
Volunteer Screening Log DOC/BA-BE/001/2025 V2.0 15/04/2025 Active

Annexure-2: Controlled Document Issuance Register

Date Document Title Issued To Version Signature
17/04/2025 ICF English Rajesh Kumar V2.0 Signed

Annexure-3: Document Access Log

Date User Document Accessed Purpose Authorized By
16/04/2025 Sunita Reddy CRF Template Subject Data Entry QA Head

Annexure-4: Document Control Deviation Form

Date Description of Deviation Root Cause CAPA Closed By
15/04/2025 Old ICF used Uncontrolled printout Document log revised QA Officer

Revision History:

Revision Date Revision No. Details Reason Approved By
15/01/2022 1.0 Initial Release GCP Compliance QA Head
17/04/2025 2.0 Expanded scope, added electronic document control and CAPA sections Audit Requirement QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Analytical Method Development: Water Content Method Development (Karl Fischer) – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version